Join the club for FREE to access the whole archive and other member benefits.

Proposed strategy to protect elderly from gerolavic infections like COVID-19

To benefit long term global health and longevity, and enhance economic recovery


Key points from article :

Clinical trials proposed for low-dose rapamycin (LDR) to protect elderly from COVID-19.

And meta-analysis of geroprotective and senoremediative strategies as a solution.

LDR once a week, combined with metformin and other geroprotectors for prevention.

Such as nicotinamide riboside, nicotinamide mononucleotide, metformin.

To track efficacy, use of inexpensive and minimally-invasive deep aging clocks proposed.

COVID-19 and other infections more harmful to elderly, to be called gerolavic infections.

Postulated geroprotectors, rapamycin, decreased infection rates elderly patients sample.

May enhance resilience against infections and reduce the severity of symptoms.

Efforts are underway to identify new geroprotectors using AI and human data.

Proposed that increases in productive longevity will substantially boost economic growth.

Innovative strategies now needed for prevention, treatment of COVID-19 in elderly.

Research by Alex Zhavoronkov, PhD, published in Aging.

Mentioned in this article:

Click on resource name for more details.


Bio-medical journal covering research on all aspects of gerontology

Alex Zhavoronkov

CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation

Biogerontology Research Foundation

Non-profit company focused on Longevity industry and gerontology

Insilico Medicine

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

King's College London

Public research university

Topics mentioned on this page:
Ageing Research, Pandemics